Correspondence 0001493152-23-043595 from Enveric Biosciences, Inc. (ENVB)
Enveric Biosciences, Inc.
Date: Dec. 4, 2023 · CIK: 0000890821 · Accession: 0001493152-23-043595
AI Filing Summary & Sentiment
File numbers found in text: 333-275380
Show Raw Text
CORRESP
1
filename1.htm
December
4, 2023
VIA
EDGAR
United
States Securities and Exchange Commission
Division
of Corporation Finance
100
F Street, N.E.
Washington,
D.C. 20549
RE: Enveric
Biosciences, Inc.
Registration
Statement on Form S-1
(File
No. 333-275380)
Acceleration
Request
Requested
Date: December 5, 2023
Requested
Time: 4:30 p.m., Eastern Time
Ladies
and Gentlemen:
Pursuant
to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), Enveric Biosciences, Inc. (the “Company”)
requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities
and Exchange Commission (the “Commission”) at the “Requested Date” and “Requested Time” set forth
above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation
Finance of the Commission.
Please
call Bradley J. Wyatt of Dickinson Wright PLLC at (734) 623-1905 to confirm the effectiveness of the Registration Statement or with any
questions.
Very
truly yours,
Enveric
Biosciences, Inc.
By:
/s/
Joseph Tucker
Name:
Joseph
Tucker, PhD
Title:
Chief
Executive Officer